PharmaSphere: US Healthcare Policy Update – Impact Analysis of the Affordable Care Act on Stakeholders

Pages: 85 Published: November 01, 2013 Report Code: GDHC004PSR

GlobalData’s PharmaSphere: US Healthcare Policy Update – Impact Analysis of the Affordable Care Act on Stakeholders report provides essential information and analysis on the Affordable Care Act (ACA). GlobalData provides an in-depth analysis of the most significant provisions of the Act, which is expected to alter the landscape of the US healthcare system considerably. The report discusses the timeline of the ACA’s provisions as well as the potential impact of these provisions on various stakeholders in the US healthcare system including payers, providers, and pharmaceutical companies. Furthermore, the report analyzes current trends as various stakeholders position themselves to benefit from the ongoing healthcare reform in the US. The report also provides an outlook on what to expect with the full implementation of the provisions of the ACA. Throughout the report, GlobalData’s analysts provide you with expert insight, expanding on each provision, strategy, and factor discussed, with the aim of providing you with the tools needed for making informed business decisions in a rapidly changing US healthcare system.

Scope

The report provides a timeline of the ACA provisions and the potential impact on various stakeholders in the US healthcare system including providers, payers, and pharmaceutical companies

The report discusses the dynamics of the US pharmaceutical industry including generics, biosimilars, and the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012

The report contains expert insights on the strategies being used by these stakeholders to ensure that they benefit significantly from the implementation of the ACA’s provisions

The report includes an outlook on future trends that are expected in the US healthcare system due to impact of the ACA

Reasons to Buy

N/A

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Report Scope

2.2Upcoming Related Reports

2.3Recently Published Reports

3Industry Dynamics

3.1Soaring Expenditures in the US Healthcare System

3.1.1US Healthcare Spending and Funding: Following the Healthcare Dollars

3.1.2Generics: A Cost-Effective Option

3.2Biosimilars: Proponents and Opponents

3.2.1State Legislative Tussles

3.3The Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012

4US Healthcare Reform

4.1Overview

4.2The Individual Mandate Provision

4.2.1The US Supreme Court Ruling

4.3Affordable Care Act Implementation Timeline

4.3.12010: Provisions Primarily Targeted at Increasing Healthcare Coverage

4.3.22011: Additional Rebates for Pharma

4.3.32012: The Emergence of Accountable Care Organizations

4.3.4What’s New in 2013?

4.3.5Beyond 2013 (2014–2018)

5Stakeholders’ Analysis

5.1Budgetary Impact of Insurance Coverage Provisions in the Affordable Care Act

5.2Providers

5.2.1Medicaid Expansion will increase Patient Volume

5.2.2Looming Healthcare Access Problems?

5.2.3Potential Increase in Quality of Healthcare Services

5.3Payers

5.3.1Increase in Member Volume by Insurance Exchanges

5.3.2New Taxes and Industry Fees on Health Insurance Payers

5.3.3Tiered-Provider Networks Continue to Be a Cost-Containment Strategy

5.4Pharmaceutical Manufacturers

5.4.1The Affordable Care Act: What’s in it for Pharmaceutical Manufacturers?

5.4.2Prescription Drug Spending Will Grow to over $480 Billion by 2021

6Strategic Outlook: The Way Forward

6.1Obamacare Will Get “Rolling” Evaluation

6.2Significant Shuttling Expected within Health Insurance Plans

6.3The Pie Gets Even Bigger for Pharmaceutical Companies

6.4Pharmacies Will Cash-in on Obamacare

7Appendix

7.1Bibliography

7.2Abbreviations

7.3Research Methodology

7.3.1Coverage

7.3.2Secondary Research

7.3.3Expert Panel Validation

7.4About the Authors

7.4.1Analyst

7.4.2Director of Healthcare Industry Dynamics

7.4.3Global Director of Epidemiology and Health Policy

7.4.4Global Head of Healthcare

7.5About the Industry Dynamics Team

7.6About GlobalData

7.7Disclosure Information

7.8Disclaimer

List of Tables

List of Tables

Table 1: Federal Medical Assistance Percentage for States with Newly Enrolled Medicaid Members

Table 2: Provisions of the Affordable Care Act Implemented in 2010

Table 3: Provisions of the Affordable Care Act Implemented in 2011

Table 4: Provisions of the Affordable Care Act Implemented in 2012

Table 5: Provisions of the Affordable Care Act Implemented in 2013

Table 6: Provisions of the Affordable Care Act to be Implemented in 2014–2018

Table 7: Estimate of Budgetary Effects of Coverage Provisions in the Affordable Care Act

Table 8: Annual Fees to be Generated from Health Insurance Providers from 2014

Table 9: Planned Reduction in Medicare Part D Coinsurance Rate for Branded and Generic Drugs,

2013–2020

Table 10: Annual Fees to Be Generated from Branded Drug Companies, 2012–2019

List of Figures

Figure 1: US Healthcare Expenditures and GDP, 2003–2012

Figure 2: US Per Capita Healthcare Expenditures and GDP, 2003–2012

Figure 3: US Personal Healthcare Spending by Service/Product, 2012

Figure 4: US Personal Healthcare Spending by Service/Product,1 2013–2021

Figure 5: US Healthcare Spending by Source of Funding,1 2012

Figure 6: US Healthcare Spending by Source of Funding,1 2010–2012

Figure 7: State Positions on Medicaid Expansion1

Figure 8: Timeline of Affordable Care Act Provisions Impacting Providers

Figure 9: Timeline of Affordable Care Act Provisions Impacting Payers

Figure 10: Domestic Exports of Pharmaceutical Products from the US, 1996–2011

Figure 11: Timeline of Affordable Care Act Provisions Impacting Pharmaceutical Companies

Figure 12: US Expenditures (Historical and Forecast) on Medicinal Products,1 2011–2021

Figure 13: Prescription Drug Expenditures,1 2011–2021

Figure 14: Prescription Drug Expenditures in the US (with and without the Affordable Care Act),

2011–2021

$2,995

Can be used by individual purchaser only

$8,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

Still undecided about purchasing this report?

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods